PCN43 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN ITALY
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71939-8
https://www.valueinhealthjournal.com/article/S1098-3015(11)71939-8/fulltext
Title :
PCN43 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN ITALY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71939-8&doi=10.1016/S1098-3015(11)71939-8
First page :
A259
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
100